Gene therapy

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High throughput screening #Lead discovery #Medicinal chemistry #Patent Law #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Ion Channel Drug Targets: Unlocking the potential

Ion Channel Drug Targets: Unlocking the potential By Dr Dayle S. Hogg, Dr Philip Boden, Dr Geoff Lawton and Dr Roland Z. Kozlowski A striking number of drugs targeting ion channels have reached blockbuster status, generating $ billion revenues. In spite of the historical success of ion channels as therapeutic… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Automation / robotics #Business #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Patent Law #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

The Timetable of Invention and it’s Relevance to Drug Discovery

The Timetable of Invention and it's Relevance to Drug Discovery By Dr William Bains The most critical question to any investor in new technology should not be whether a technology will work. Technologies nearly always work in the end, providing they do not break fundamental laws of physics, and are… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Business #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #Lead discovery #Molecular medicine #Organic chemistry #Orphan drugs #Protein chemistry / Proteomics #RNA #System biology #Systems biology #Therapeutics

Whither Pharma? The demise of pharma’s blockbuster business model

By Dr Alpheus Bingham It has been suggested that the blockbuster business model, which has been the key to big pharma success, is now broken and completely beyond repair. In a truly global and fast changing business world, is it time to examine alternatives to the classic monolithic risk structure… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #Target validation #Therapeutics

Silence For Health – Development of RNA interference based cancer therapy

Silence For Health - Development of RNA interference based cancer therapy By Dr Ansgar Santel RNA interference (RNAi) has become an invaluable tool for biomedical research. It is already routinely used as an indispensable approach for gene function analysis in basic biological research and for target identification as well as… Read More

#Archive

#Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Microfluidics #Molecular medicine #Nanomedicine / nanotechnology #Organic chemistry #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

The Role of Nanotechnology in Drug Discovery

By Dr Amarpreet S Dhiman In terms of drug discovery and development, the role of nanotechnology currently lies in improving diagnostic methods, developing improved drug formulations and drug delivery systems for disease therapy. The breakthrough format of nanotechnology offers innovative solutions, giving researchers greater analytical capacity, improved data quality and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #Oncology #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Toxicology #Translational #Translational chemistry

Understanding the strategic importance of BIOMARKERS for the discovery and early development phases

Share Share Tweet Email Understanding the strategic importance of BIOMARKERS for the discovery and early development phases Understanding the strategic importance of BIOMARKERS for the discovery and early development phases By Dr Orest Hurko Biomarkers have become an increasingly hot topic in the pharmaceutical industry. How much of this is… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Metabolomics #Oncology #Orphan drugs #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

METABOLOMICS – A ‘systems’ contribution to pharmaceutical discovery and drug development

By Dr George G. Harrigan The potential of metabolomics, a systems approach to biochemical pathway analysis, to yield scientific and commercial benefits to healthcare and biotechnology enterprises is increasingly recognised. This article discusses current applications and future developments and places an emphasis on incorporation of metabolomics within all aspects of… Read More

#Archive

#ADME / Tox #Analysis #Assay development & optimisation #Biochemistry #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #PCR #Preclinical #Screening #System biology #Systems biology #Target validation

Development of an HTS FabD inhibition assay using a new 384-well filter plate to screen novel antibiotics

Development of an HTS FabD inhibition assay using a new 384-well filter plate to screen novel antibiotics by Dr Gatan Touyer, Dr Christine Miossec, and Dr Irvin Winkler Several enzymes are involved in the fatty acid biosynthesis (Fab) system of bacterial organisms. Unlike the mammalian FAS enzyme system in which… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Lead discovery #Orphan drugs #Regulatory #RNA

Personalised Medicine: What’s in it for big pharma?

Personalised Medicine: What's in it for big pharma? By Dr Stephen Little There is nothing more difficult to take in hand, more perilous to conduct, or more uncertain in its success, than to take the lead in the introduction of a new order of things. Because the innovator has far… Read More

#Archive

#Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Lead discovery #Molecular medicine #RNA #Therapeutics #Toxicology

Next Generation HIV Drugs move into late stage development

Next Generation HIV Drugs move into late stage development By Dr Graham P. Allaway and Dr Jeffrey M. Jacobson There are currently 24 drugs approved for treating HIV infection. Of these, 23 are small molecule orally available drugs, or drug combinations, targeting the virus' reverse transcriptase and protease enzymes, targets… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #Molecular medicine #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Advances in the imaging of biomolecules: the label-free intrinsic imaging approach

Advances in the imaging of biomolecules: the label-free intrinsic imaging approach By Dr Stuart Hassard, Dr Anthony D. Baxter and Dr John Hassard Many stages in the process of drug discovery require the separation, identification and analysis of biomolecules such as proteins, peptides and nucleic acids. Such analyses have traditionally… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Next Decade of Gene Expression Profiling

By Dr Y. Douglas Dolginow The art and science of prediction is a risky and humiliating exercise. As bad as we are at it, predicting things remains one of the fundamental human instincts, undoubtedly linked to a Darwinian selective advantage for our species. So no matter that the umbrella was… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Lead discovery #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Pharmokinetics #Regulatory #RNA #Screening #Stem cells #Therapeutics #Toxicology

Nanotechnology approaches to solving the problems of poorly water-soluble drugs

Nanotechnology approaches to solving the problems of poorly water-soluble drugs By Dr Roghieh Saffie-Siebert, Dr Jill Ogden and Dr Mark Parry-Billings Traditionally, almost half of new molecular entities identified by pharmaceutical industry screening programmes have failed to be developed because of poor water-solubility, which makes their formulation difficult or even… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Business #Cell therapy #Chemical engineering #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Lead optimisation #Pharmacology #Pharmokinetics #Preclinical #Regulatory #Screening #Toxicology

Exposure response modelling a safe and profitable way to speed drugs to market

Exposure response modelling a safe and profitable way to speed drugs to market By Dr Gregory Fisher and Dr Arthur L. Craigmill The applicability of physiologically-based pharmacokinetic modelling (PBPK) far exceeds that of classical PK in predictive pharmacokinetics, tissue dosimetry, drug efficacy, and drug safety. This in silico technique, in… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microfluidics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Overview of biomarkers in disease, drug discovery and development

Overview of biomarkers in disease, drug discovery and development By Professor Stephen Naylor The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency. The parallels between the problems of producing new therapeutic agents and treating patients afflicted… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Lead discovery #Molecular medicine #Oncology #Organic chemistry #Regulatory #RNA #Sequencing #Stem cells #Therapeutics #Toxicology

COX-2 Inhibitor Toxicity – Warning shot over pharma’s bow

COX-2 Inhibitor Toxicity - Warning shot over pharma's bow By Dr Mark Schena and Dr William Greene Human beings are complex gene machines that rely on the intricate interplay of ~25,000 genes to impart biological function. Genomic function is affected by genetic variability and environmental factors, giving rise to considerable… Read More

#Archive